Guardian

Dramatic dip in baby hospitalizations for RSV linked to vaccine and treatment

GAVI

Roll-out of RSV vaccine and antibody treatment leads to massive drop in US hospitalisations

Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products  United States, October 

Global Citizen

Whats Next for Gavi, the Vaccine Alliance

Medscape

RSV Vaccination Associated With Fewer Infant Hospitalizations

Science News

RSV wasnt as hard on U.S. babies last winter. This may be why

MedPage Today

Published Data Show Why GSK Bailed on Its Maternal RSV Vaccine

<span>National immunization survey data shows the proportion of US infants aged 0-7 months protected by either maternal vaccination or nirsevimab reached 66% by February 2025, marking a substantial increase from 30% in October 2024, demonstrating rapid adoption of these preventive measures.</span

National immunization survey data shows the proportion of US infants aged 0-7 months protected by either maternal vaccination or nirsevimab reached 66% by February 2025, marking a substantial increase from 30% in October 2024, demonstrating rapid adoption of these preventive measures.

<span>RSV remains a significant global health threat, causing 33 million cases of lower respiratory tract infections and 3.6 million hospitalizations annually in children under five years old, with the virus being the second leading cause of infant mortality after malaria.</span

RSV remains a significant global health threat, causing 33 million cases of lower respiratory tract infections and 3.6 million hospitalizations annually in children under five years old, with the virus being the second leading cause of infant mortality after malaria.

<span>The CDC study utilized two surveillance networks (RSV-NET and NVSN) to compare hospitalization rates, revealing that RSV hospitalizations in newborns decreased by 52% in RSV-NET and 45% in NVSN, with even greater reductions when excluding early outbreak data from Houston.</span

The CDC study utilized two surveillance networks (RSV-NET and NVSN) to compare hospitalization rates, revealing that RSV hospitalizations in newborns decreased by 52% in RSV-NET and 45% in NVSN, with even greater reductions when excluding early outbreak data from Houston.

<span>While the vaccines showed promising results for infants under eight months, children aged 1-4 and 5-17 experienced higher rates of hospitalization this winter compared to previous seasons, suggesting the season may have been more severe overall.</span

While the vaccines showed promising results for infants under eight months, children aged 1-4 and 5-17 experienced higher rates of hospitalization this winter compared to previous seasons, suggesting the season may have been more severe overall.

<span>A meta-analysis of six randomized controlled trials involving over 12,600 pregnant women and their infants demonstrated varying effectiveness among vaccine candidates, with WyethLederle's RSV-PFP-2 vaccine showing a 50% reduction in medically attended RSV infections.</span

ContagionLive

A meta-analysis of six randomized controlled trials involving over 12,600 pregnant women and their infants demonstrated varying effectiveness among vaccine candidates, with WyethLederle's RSV-PFP-2 vaccine showing a 50% reduction in medically attended RSV infections.

Guardian #6232

GAVI #

CDC #

Global Citizen #

Medscape #

Science News #

MedPage Today #

<h2></h2>

Infectious diseases

United States of America

Vaccination

Safety concerns remain a significant consideration in maternal RSV vaccination programs. One vaccine candidate showed a 37% increase in preterm birth rates, highlighting the need for enhanced monitoring and careful risk-benefit analysis. The challenge of developing new vaccines while maintaining competitive advantage and managing public perception creates additional barriers to advancing RSV prevention options.

<span>Safety concerns remain a significant consideration in maternal RSV vaccination programs. One vaccine candidate showed a 37% increase in preterm birth rates, highlighting the need for enhanced monitoring and careful risk-benefit analysis. The challenge of developing new vaccines while maintaining competitive advantage and managing public perception creates additional barriers to advancing RSV prevention options.</span>

Maternal RSV Vaccines Show Promise for Infant Protection but Raise Safety Concerns

New RSV Vaccines Cut Infant Hospitalizations by Up to 71%

New RSV Vaccines Cut Infant Hospitalizations by Up to 71%

DramaticNew dipRSV inVaccines babyCut hospitalizationsInfant forHospitalizations RSVby linkedUp to vaccine and treatment71%

The Spin

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

New RSV Vaccines Cut Infant Hospitalizations by Up to 71%

DramaticNew dipRSV inVaccines babyCut hospitalizationsInfant forHospitalizations RSVby linkedUp to vaccine and treatment71%

The Spin

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters